Travere Therapeutics (TVTX) Profit After Tax (2016 - 2025)
Historic Profit After Tax for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to $25.7 million.
- Travere Therapeutics' Profit After Tax rose 14689.93% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.5 million, marking a year-over-year increase of 7480.78%. This contributed to the annual value of -$321.5 million for FY2024, which is 1455.84% up from last year.
- Travere Therapeutics' Profit After Tax amounted to $25.7 million in Q3 2025, which was up 14689.93% from -$12.8 million recorded in Q2 2025.
- In the past 5 years, Travere Therapeutics' Profit After Tax registered a high of $150.7 million during Q3 2023, and its lowest value of -$136.1 million during Q1 2024.
- Its 5-year average for Profit After Tax is -$54.6 million, with a median of -$70.4 million in 2024.
- As far as peak fluctuations go, Travere Therapeutics' Profit After Tax plummeted by 676670.79% in 2021, and later soared by 27931.19% in 2023.
- Quarter analysis of 5 years shows Travere Therapeutics' Profit After Tax stood at -$88.8 million in 2021, then rose by 3.53% to -$85.6 million in 2022, then fell by 5.3% to -$90.2 million in 2023, then surged by 33.17% to -$60.3 million in 2024, then surged by 142.66% to $25.7 million in 2025.
- Its last three reported values are $25.7 million in Q3 2025, -$12.8 million for Q2 2025, and -$41.2 million during Q1 2025.